This letter highlights methodological flaws and potential biases in a recent cost-effectiveness analysis comparing advanced hybrid closed-loop systems to intermittently scanned continuous glucose monitoring in type 1 diabetes.
A recent publication in Diabetes Therapy from Jendle and colleagues [1] reports on the costeffectiveness of the MiniMed 780G advanced hybrid closed-loop (AHCL) system (Medtronic, Northridge, CA) in people with type 1 diabetes (T1DM) in Sweden, by comparison with the intermittently scanned FreeStyle Libre Ò flash glucose monitoring system (Abbott, Witney, UK) when used in conjunction with multiple daily insulin injections (MDI) or with continuous subcutaneous insulin infusion (CSII).The authors conclude that the MiniMed 780G AHCL is cost-effective compared to the FreeStyle Libre system plus MDI or CSII for treating people with T1DM.We must argue that this conclusion depends on modelling assumptions that have the potential to introduce bias into the
No takes yet. Share an insight, caveat, or question.
Levrat‐Guillen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: